Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...

MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...

The Wegovy pill comes in tablet form—and is the first U.S. Food & Drug Administration (FDA)-approved GLP-1 to do so. Its ...

People taking weight-loss drugs are likely to regain the weight they have lost within two years of stopping the medications, ...

The new oral drug costs as little as $149 a month out of pocket and is expected to broaden access as demand for GLP-1 ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

In this week’s Medical Minute, Dr. Lacey Anderson said the first oral GLP-1 medication for weight loss, a pill version of ...

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking ...